UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SAN DIEGO, March 05, 2018 -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2017 financial results after the close of U.S. financial markets on Monday, March 12, 2018. Kura Oncology’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international callers and entering the conference code: 5196505. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
Contacts
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
Kura Oncology, Inc.
(858) 500-8803
[email protected]
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
[email protected]
